Project Grant R00HL166693
Award Date
7/1/25
Completion Date
6/30/28
Dollars Obligated
$249K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This Project Grant award for $547,020.00, provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to establish an Organoid-AI system for assessing cardiotoxicity induced by Tyrosine Kinase Inhibitors (TKIs) used in cancer treatment. The central goal is to develop a comprehensive in vitro human model using Pluripotent Stem Cell-derived Vascularized Cardiac Organoids (VCOs) to accurately predict and phenotype...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $701,890.00 to the University of Illinois to investigate the molecular mechanisms by which the cancer drug sunitinib induces vascular dysfunction. The key research aims are to: 1) define how sunitinib translationally regulates the protein SND1, 2) elucidate the role of SND1 in mediating endothelial tolerance against sunitinib's...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $149,948 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Leland Stanford Junior University to investigate the role of p53 signaling in endothelial-to-mesenchymal transition and its impact on radiation-induced coronary heart disease. The 2-year project aims to utilize human-induced pluripotent stem cells and transgenic mouse models to elucidate the functional and molecular alterations in the...
This $408,599 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the TGF-beta/SMAD3 pathway in endothelial damage and cardiac remodeling caused by doxorubicin chemotherapy. The research aims to assess how doxorubicin-induced endothelial reprogramming via this pathway contributes to the development of cardiomyopathy, and whether suppressing SMAD3...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will provide $645,460.00 to Northwestern University to conduct research on mechanisms underlying nilotinib-induced artery disease (NIAD) in chronic myelogenous leukemia (CML) patients. The objectives are to: 1) Identify genetic variants that predispose CML patients to NIAD through whole genome sequencing and functional characterization of patient-derived induced pluripotent stem...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This federal Project Grant award of $680,583 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Mayo Clinic supports research focused on discovering genetic modifiers and therapies for anthracycline-induced cardiotoxicity. The key objectives are to: Confirm FABP7 and GPNMB as therapeutic target genes for anthracycline-induced cardiotoxicity, and explore the role of cardiac aging using the killifish model. Test the hypothesis that epicardial...